86. 肺動脈性肺高血圧症 Pulmonary arterial hypertension Clinical trials / Disease details

臨床試験数 : 1,205 / 薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193

2 trials found

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05179356 (ClinicalTrials.gov)	January 1, 2023	16/12/2021	Dapagliflozin in Pulmonary Arterial Hypertension	Effects of DAPAgliflozinon Cardiopulmonary Exercise Capacity and Hemodynamics in Pulmonary Arterial ...	Pulmonary Arterial Hypertension;Chronic Thromboembolic Pulmonary Hypertension	Drug: Dapagliflozin 10 MG [Farxiga];Drug: Placebo	Mads Ersbøll	NULL	Not yet recruiting	18 Years	N/A	All	52	Phase 2	NULL
2	EUCTR2021-006787-25-DK (EUCTR)	06/07/2022	22/12/2021	The effects of dapagliflozin in patients with elevated blood pressure in the lungs	Effects of DAPAgliflozinon cardiopulmonary exercise capacity and hemodynamics in Pulmonary Arterial ...	Pulmonary arterial hypertensionChronic thromboembolic pulmonary hypertension MedDRA version: 21.1;Le ...	Trade Name: Forxiga (dapagliflozin) Product Name: Forxiga INN or Proposed INN: Dapagliflozin	Rigshospitalet The Heart Center	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	52	Phase 2	Denmark

First Previous1Next Last